Drug Profile
Minzasolmin - UCB
Alternative Names: DLX-313; UCB-0599Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Neuropore Therapies
- Developer Neuropore Therapies; UCB Biopharma
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 31 May 2023 UCB Biopharma initiates a phase I trial in Parkinson's disease (In volunteers) in USA (PO) (NCT05845645)
- 11 May 2023 UCB Pharma plans a phase I trial (In volunteers) (PO) (NCT05845645)
- 21 Sep 2022 USB Biopharma initiates a phase II trial for Parkinson's disease (In adults, In the elderly, Early stage disease) in US (PO) (NCT05543252)